Paul is an Executive Director on the Business Development & Licensing team at Merck. He is focused on search and evaluation of external pipeline opportunities for oncology and immuno-oncology, both as single agents as well as in combination with approved Merck cancer therapies such as Keytruda. Paul has over 25 years of experience in the biopharmaceutical industry. He has a unique career mix of science, strategy, and business development, and deep experience both at small biotech startups as well as global pharmaceutical companies. Prior positions include Head of Technologies, External Science & Innovation, Pfizer; Global Head, External Innovation, EMD Serono; CSO, Syndexa Pharmaceuticals; Head of Operations for Oncology Discovery and Cambridge Science Site Head, Sanofi; VP of Research, Avalon Pharmaceuticals; and Project Leader, Human Genome Sciences. Paul received his B.S. in Biology from Yale University; Ph.D. in Cellular, Molecular, & Developmental Biology from Harvard University, and completed his postdoctoral fellowship at Genentech in Immunology & Molecular Oncology.